﻿Despite great progress in the development of immune checkpoint inhibitors, particularly the encouraging therapy of PD-L1/PD-1 blockade, a portion of NSCLC patients remain generally resistant to these therapies [42]. Here, CD274 is linked to non-small cell lung carcinoma.